Protara Therapeutics found using ticker (TARA) now have 3 analysts covering the stock with the consensus suggesting a rating of ‘Strong_Buy’. The range between the high target price and low target price is between 50 and 37 with the average target price sitting at 45.67. With the stocks previous close at 24.68 this indicates there is a potential upside of 85.0%. There is a 50 day moving average of 22.35 and the 200 day MA is 23.42. The market cap for the company is $258m. You can visit the company’s website by visiting: http://www.protaratx.com
Protara Therapeutics, a clinical-stage company, engages in the identifying and advancing transformative therapies for people with rare and specialty diseases. The company’s lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics and changed its name to Protara Therapeutics in May 2020. Protara Therapeutics is based in New York, New York.
You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.
